PYXS

Pyxis Oncology, Inc.

6.43 USD
-0.04 (-0.62%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Pyxis Oncology, Inc. stock is up 80.11% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 March’s closed higher than February. 100% of analysts rate it a buy.

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.